检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:余冬保[1] 李毅[1] 梁幼生[2] 肖妙青 欧阳善文 唐坚 喻鑫玲[1] 魏望远[1]
机构地区:[1]湖南省寄生虫病防治研究所,岳阳414000 [2]江苏省寄生虫病防治研究所 [3]湖南省株洲市荷塘区血防站 [4]湖南省汉寿县坡头血防站
出 处:《中国人兽共患病杂志》2001年第5期86-88,共3页Chinese Journal of Zoonoses
基 金:世界卫生组织西太区资助项目 (SupportedbyagrantfromtheWesternPacificRegionalOfficeoftheWorldHealthOrganizationMAL/CHN/ 99/ 0 1)
摘 要:目的 现场评价洞庭湖反复化疗地区和新发现疫区现阶段吡喹酮治疗日本血吸虫病的效果。方法 应用Kato-Katz法和孵化法确定血吸虫感染者 2 3 0例 ,吡喹酮化疗 5 0天后进行第一次追踪粪检 ,阳性者再次进行化疗 ,再过 5 0天后进行第二次追踪粪检。结果 2 2 0例接受第一次追踪的对象中 ,2 2例阳性 ,虫卵阴转率为 90 % ,新老疫区阴转率比较无显著性差异。 2 1例对象接受第二次化疗 ,2 0例接受第二次粪检追踪 ,仅 1例阳性。结论 在经过 10余年大面积人畜同步化疗后 ,洞庭湖血吸虫病疫区吡喹酮化疗的效果未发生变化 ,与新疫区比较亦无显著性差异。Aim To evaluate the efficacy of praziquantel against Schistosoma japonicum in area with repeated chemotherapy as compared with that in newly found endemic area in Dongting Lake region of China.Method 230 cases infected with S.japonicum as determined by Kato-Katz technique and miracidia hatching test were administered with a single oral dose of praziquantel in the non-infection season.The first follow up stool examination was made 50 days after treatment.Another chemotherapy was given to those stool egg positives,and the second follow up stool examination was made 50 days since then.Results Among the 220 cases received the first follow up,22 were found stool egg positive,with a stool egg negative conversion rate of 90%.No significant difference was found between the new and historical endemic areas.Of the 21 cases received the second chemotherapy,20 were followed up and only 1 was still stool egg positive after two consecutive treatments.Conclusion The efficacy of praziquantel against S.japonicum has not changed in the Dongting Lake region after more than 10 years of expanded chemotherapy.The efficacy is also not significantly different from that in the newly found endemic area.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.41